Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 3/20 | 0.43 |
| ▸ | GRM5 | P41594 | 3/20 | 0.40 |
| ▸ | HTR7 | P34969 | 1/20 | 0.40 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.39 |
| ▸ | TEAD3 | Q99594 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.39 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.38 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4295523 | 0.88 | HCRTR1 (0.36) | TEAD1TEAD3HCRTR1HCRTR2 | |
| SCHEMBL3494366 | 0.87 | TEAD1 (0.50) | TEAD1TEAD3ALDH1A1 | |
| SCHEMBL4292747 | 0.87 | KDM4E (0.40) | TEAD1TEAD3ALDH1A1HCRTR1HCRTR2 | |
| SCHEMBL4287625 | 0.86 | KDM4E (0.50) | ENPP2ALDH1A1 | |
| SCHEMBL4285970 | 0.86 | KDM4E (0.51) | ALDH1A1HCRTR1HCRTR2 | |
| SCHEMBL4286428 | 0.86 | HCRTR1 (0.47) | ALDH1A1HCRTR1HCRTR2 | |
| SCHEMBL4294643 | 0.85 | KDM4E (0.43) | ALDH1A1HCRTR1HCRTR2 | |
| SCHEMBL4289699 | 0.84 | MAOB (0.45) | ALDH1A1HCRTR1HCRTR2 | |
| SCHEMBL4285558 | 0.84 | HRH3 (0.45) | ALDH1A1HCRTR1HCRTR2 | |
| SCHEMBL4294089 | 0.84 | KDM4E (0.39) | TEAD1TEAD3ALDH1A1HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227560-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20090156612-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156612-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | ENPP2 3719/4885GRM5 2278/4885HTR7 1874/4885 |
| US-20090227560-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | ENPP2 3719/4885GRM5 2278/4885HTR7 1874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.